Welcome to our dedicated page for ALLURION TECHNOLOGIES SEC filings (Ticker: ALUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Allurion Technologies, Inc. (NYSE: ALUR) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed information about Allurion’s medical device business focused on metabolically healthy weight loss, its Allurion Program, and the Allurion Smart Capsule, which the company describes as a swallowable, Procedureless™ gastric balloon for weight loss and an investigational device in the United States.
Through periodic reports and current reports on Form 8-K, Allurion outlines financial results, capital structure changes, and governance matters. Filings referenced in recent disclosures include notifications of late filing on Form 12b-25, restatements related to accounting for a revenue interest financing agreement and convertible senior secured notes, and descriptions of material weaknesses in internal control over financial reporting. Investors can review these filings to understand how non-cash accounting adjustments affect items such as Other Comprehensive Income (Loss) and Other Income (Expense), as well as the company’s commentary that these corrections are not expected to impact revenue, gross margin, operating expenses, or cash.
Allurion’s SEC filings also describe capital markets and financing transactions, such as a private placement of common stock and accompanying warrants, and an exchange agreement to convert outstanding debt and obligations under revenue interest financing agreements into shares of Series B convertible preferred stock, subject to stockholder approval and exchange listing requirements. Definitive proxy materials provide further detail on proposals for stockholders, including amendments to stock plans, option repricing, preferred share and warrant share issuances, and a potential reverse stock split within an approved ratio range.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain the key points of complex documents like 10-Ks, 10-Qs, 8-Ks, and proxy statements in plain language. Users can quickly see the main themes in Allurion’s disclosures on regulatory progress for the Allurion Smart Capsule, financial performance, risk factors, and governance decisions, while still having access to the full original SEC documents for deeper analysis.
Allurion Technologies, Inc. describes its business as a metabolically focused weight loss platform built around the Allurion Program, which combines the swallowable Allurion Smart Capsule gastric balloon with an AI-powered Virtual Care Suite for remote monitoring and behavior change.
The company highlights more than 200,000 patients treated across over 50 countries and positions its program as complementary to GLP-1 drugs. It reports FDA PMA approval in the United States for the Allurion Gastric Balloon System for adults with obesity, enabling U.S. commercialization. Recent financing steps include a November 2025 private placement and a February 2026 warrant inducement that raised cash but added new warrants.
Allurion also discloses NYSE minimum market-capitalization non-compliance and ongoing appeals of delisting determinations, with its common stock now trading on the OTC market and plans to seek a higher-tier OTC listing. The company emphasizes a large obesity market opportunity, a broad patent and trademark portfolio, and a strategy focused on global expansion, U.S. launch, and a path to profitability.
Allurion Technologies received notice that the New York Stock Exchange will begin proceedings to delist its common stock and warrants after the company failed to meet the NYSE rule requiring an average global market capitalization of at least $15,000,000 over 30 consecutive trading days. Trading on the NYSE was suspended after market close on March 6, 2026, and the shares now trade on the OTCID Market under the same symbols while Allurion appeals the decision.
The company recently obtained U.S. FDA approval for its Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, and has presented the NYSE with a multi-step plan to regain compliance or qualify for listing on NYSE American, strengthen its balance sheet, and fund U.S. commercialization of the Smart Capsule. Management cautions there is no assurance the appeal or relisting efforts will succeed, and notes that liquidity, trading volume and broker quoting on the OTC market may be limited.
Allurion Technologies, Inc. large shareholder RTW-affiliated entities filed an amended Schedule 13D to update their beneficial ownership of the company’s common stock.
RTW Investments, LP and Roderick Wong report beneficial ownership of 5,891,430 shares, representing 39.4% of Allurion’s common stock, with shared voting and dispositive power. RTW Master Fund, Ltd holds 3,138,798 shares (21.0%), and RTW Innovation Master Fund, Ltd holds 2,427,089 shares (16.2%), all on a shared basis.
The ownership percentages are calculated from shares outstanding reported in a January 2026 prospectus plus additional shares issued under an Inducement Offer to Exercise Common Stock Purchase Warrants that closed on February 26, 2026. The filing states that no transactions in Allurion securities were made by the reporting persons in the past sixty days and that the higher percentage figures reflect an increase in Allurion’s outstanding shares.
Allurion Technologies reported that the New York Stock Exchange plans to begin delisting proceedings because the company no longer meets the NYSE rule requiring at least $50 million in stockholders’ equity or a $50 million average market value. Allurion will appeal this determination to an NYSE board committee, and its common stock and warrants are expected to continue trading on the NYSE during the review period, provided it meets other listing requirements.
The company is pursuing several steps to regain compliance or qualify for listing on another exchange, including capital-raising efforts, negotiations with creditors and security holders, an agreement to exchange all outstanding debt for preferred stock at a premium to the current share price, and a recent warrant inducement transaction. Management warns that there is no assurance the appeal or these initiatives will succeed, and notes that any ultimate delisting could reduce liquidity, pressure the share price, limit access to public capital markets, and weaken its ability to grant equity incentives.
Allurion Technologies entered into a warrant exercise inducement agreement with certain existing warrant holders. The company cut the exercise price of its outstanding warrants to $1.15 per share and the participating holders agreed to exercise warrants for an aggregate 2,659,565 shares of common stock.
In return, Allurion will issue new warrants to these holders to purchase up to 5,319,130 additional shares of common stock at $1.15 per share. The company expects to receive approximately $3.0 million in gross cash proceeds from the warrant exercises. The new warrants will become exercisable after stockholder approval, will expire five years after that date, and are subject to beneficial ownership limits of 4.99% or 9.99% at the holders’ option.
Allurion engaged Roth Capital Partners as financial advisor and will pay a fee equal to 5.0% of the gross proceeds from the warrant exercises, plus up to $40,000 for related expenses. The company also agreed to file a registration statement to cover resale of shares underlying the new warrants within 60 days of the inducement letter.
Allurion Technologies reported that the U.S. Food and Drug Administration granted premarket approval for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule, for adults aged 22–65 with obesity and a BMI between 30 and 40 kg/m2 after at least one unsuccessful weight-loss attempt.
The Smart Capsule is swallowed in a brief office visit, forms a gastric balloon that remains in the stomach for about four months, then empties and passes naturally, with the option for a second capsule within a 10‑month treatment period. Allurion estimates this indication provides access to roughly 80 million Americans within the approved BMI range.
The company highlights prior use of the Smart Capsule outside the United States in over 200,000 patients and cites published data showing around 14% total body weight loss with one balloon cycle and over 20% with two cycles or when combined with low‑dose GLP‑1 therapies. Allurion also notes risks around maintaining FDA approval, successful commercialization, and obtaining sufficient financing to continue as a going concern.
Allurion Technologies, Inc. has registered 5,988,024 shares of common stock for potential resale by existing securityholders. The shares include 2,994,012 shares issued in a November 2025 private placement and 2,994,012 shares issuable upon exercise of accompanying warrants with a $1.67 exercise price. The company will not receive proceeds from any resale of these shares but could receive up to approximately $5.0 million if all November 2025 warrants are exercised for cash. As of January 5, 2026, 12,279,181 shares of common stock were outstanding. The prospectus notes that large or sustained resales could put pressure on the stock price. Allurion remains an emerging growth and smaller reporting company and highlights recent financing steps and an exchange agreement with RTW tied to Series B preferred stock and specified performance conditions.
Allurion Technologies, Inc. furnished an update on its business by disclosing that it issued a press release with selected preliminary financial results for the quarter and year ended December 31, 2025. The company states that the full text of this press release is provided as Exhibit 99.1 and is incorporated by reference. The information about these preliminary results is being furnished under the rules governing current reports and is expressly described as not being "filed" for liability purposes under the Exchange Act.
Allurion Technologies, Inc. has filed a resale registration covering up to 5,988,024 shares of common stock that may be sold from time to time by existing investors. This total consists of 2,994,012 shares issued in a November 2025 private placement and 2,994,012 shares issuable upon exercise of accompanying November 2025 Private Placement Warrants. Allurion will not receive proceeds from investors’ resale of these shares, but could receive up to approximately $5.0 million if all of the warrants are exercised in cash at an exercise price of $1.67 per share. As of January 5, 2026, 12,279,181 shares of common stock were outstanding. The company highlights that large, ongoing resales under this prospectus could put pressure on its stock price. Allurion develops a weight-loss platform built around its swallowable, procedure-free intragastric balloon and a digital Virtual Care Suite.